Prophylactic mRNA vaccination against allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 6, 2010, Pages 567-574

  Weiss, Richard ^a   Scheiblhofer, Sandra ^a   Roesler, Elisabeth ^a   Ferreira, Fatima ^a   Thalhamer, Josef ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

allergy; immunotherapy; mRNA; vaccine

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN E; RNA VACCINE;

ALLERGY; ANTIBODY RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG TRANSPORT; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTRACELLULAR TRANSPORT; LUNG INFILTRATE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RNA IMMUNIZATION; RNA REPLICATION; SHELF LIFE; TH1 CELL;

ANIMALS; COST-BENEFIT ANALYSIS; CYTOKINES; DRUG STABILITY; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; MICE; RNA, MESSENGER; TH1-TH2 BALANCE; VACCINATION;

EID: 78449257794     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833fd5b6     Document Type: Review

References (45)

1. Marenholz I, Kerscher T, Bauerfeind A, et al. An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J Allergy Clin Immunol 2009; 123:911-916.
2. Kulig M, Bergmann R, Niggemann B, et al. Prediction of sensitization to inhalantallergens in childhood: evaluating family history, atopic dermatitisand sensitization to food allergens. The MAS Study Group. Multicentre Allergy Study. Clin Exp Allergy 1998; 28:1397-1403.
3. Senthilselvan A, Rennie D, Chenard L, et al. Association of polymorphisms of Toll-like receptor 4 with a reduced prevalence of hay fever and atopy. Ann Allergy Asthma Immunol 2008; 100:463-468.
4. Tighe H,Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106:124-134.
5. Weiss R, Scheiblhofer S, Gabler M, et al. Isgeneticvaccination againstallergy possible? Int Arch Allergy Immunol 2006; 139:332-345.
6. Chua KY, Kuo IC, Huang CH. DNA vaccines for the prevention and treatment of allergy. Curr Opin Allergy Clin Immunol 2009; 9:50-54.
7. Manam S, Ledwith BJ, Barnum AB, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000; 43:273-281.
8. Martin T, Parker SE, Hedstrom R, et al. Plasmid DNA malaria vaccine: the potentialforgenomic integration afterintramuscularinjection. Hum Gene Ther 1999; 10:759-768.
9. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-1468.
10. Conry RM, LoBuglio AF, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995; 55:1397-1400.
11. Hoerr I, Obst R, Rammensee HG, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30:1-7.
12. Granstein RD, Ding W, Ozawa H. Induction of antitumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 2000; 114:632-636.
13. Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31:180-188.
14. Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32:498-507.
15. Kuhn AN, Diken M, Kreiter S, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010; 17:961-971.
16. Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108:4009-4017.
17. Grillo G, Turi A, Licciulli F, et al. UTRdb and UTRsite (RELEASE 2010): a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. Nucleic Acids Res 2010; 38:D75-D80.
18. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999; 18:765-777.
19. Leitner WW, Hwang LN, Bergmann-Leitner ES, et al. Apoptosis is essential forthe increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004; 22:1537-1544.
20. Leitner WW, Bergmann-Leitner ES, Hwang LN, et al. Type I interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006; 24:5110-5118.
21. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5:730-737.
22. Diebold SS, Schulz O, Alexopoulou L, et al. Role of TLR3 in the immuno-genicity of replicon plasmid-based vaccines. Gene Ther 2009; 16:359-366.
23. Scheel B, Braedel S, Probst J, et al. Immunostimulating capacities of stabi-lized RNA molecules. Eur J Immunol 2004; 34:537-547.
24. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-1531.
25. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004; 303:1526-1529.
26. Roesler E, Weiss R, Weinberger EE, et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009; 124:1070-1077; e1-e11.
27. Guo PX, Moss B. Interaction and mutual stabilization of the two subunits of vaccinia virus mRNA capping enzyme coexpressed in Escherichia coli. Proc Natl Acad Sci USA 1990; 87:4023-4027.
28. Probst J, Brechtel S, Scheel B, et al. Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther 2006; 4:4.
29. Probst J, Weide B,Scheel B, et al.Spontaneouscellular uptakeof exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther 2007; 14:1175-1180.
30. Budker V, Budker T, Zhang G, et al. Hypothesis: naked plasmid DNA istaken up by cells in vivo by a receptor-mediated process. J Gene Med 2000; 2:76-88.
31. Wolff JA, Dowty ME, Jiao S, et al. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skelet al muscle. J Cell Sci 1992; 103 (Pt 4):1249-1259.
32. Basner-Tschakarjan E, Mirmohammadsadegh A, Baer A, et al. Uptake and trafficking of DNA in keratinocytes: evidence for DNA-binding proteins. Gene Ther 2004; 11:765-774.
33. Trombone AP, Silva CL, Lima KM, et al. Endocytosis of DNA-Hsp65 alters the pH of the late endosome/lysosome and interferes with antigen presentation. PLoS One 2007; 2:e923.
34. Schubbert R, Renz D, Schmitz B, et al. Foreign (M13) DNA ingested by mice reaches peripheral leukocytes, spleen, and liverviathe intestinal wall mucosa and can be covalently linked to mouse DNA. Proc Natl Acad Sci USA 1997; 94:961-966.
35. Levy MY, Barron LG, Meyer KB, et al.Characterization of plasmid DNA transfer into mouse skelet al muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther 1996; 3:201-211.
36. Saleh MC, van Rij RP, Hekele A, et al. The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nat Cell Biol 2006; 8:793-802.
37. Lehmann MJ, Sczakiel G. Spontaneous uptake of biologically active recom-binant DNA by mammalian cells via a selected DNA segment. Gene Ther 2005; 12:446-451.
38. Wheeler M, Cortez-Gonzalez X, Frazzi R, et al. Ex vivo programming of antigen-presenting B lymphocytes: considerations on DNA uptake and cell activation. Int Rev Immunol 2006; 25:83-97.
39. Lechardeur D, Lukacs GL. Nucleocytoplasmic transport of plasmid DNA: a perilous journey from the cytoplasm to the nucleus. Hum Gene Ther 2006; 17:882-889.
40. Ponsaerts P, Van Tendeloo VF, Berneman ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 2003; 134:378-384.
41. Strobel I, Berchtold S, Gotze A, et al. Human dendritic cells transfected with eitherRNAor DNAencoding influenzamatrix protein M1 differin theirabilityto stimulate cytotoxic T lymphocytes. Gene Ther 2000; 7:2028-2035.
42. Scheiblhofer S, Gabler M, Leitner WW, et al. Inhibition of type I allergic responses with nanogram doses of replicon-based DNA vaccines. Allergy 2006; 61:828-835.
43. Scheiblhofer S, Stoecklinger A, Gruber C, et al. Gene gun immunization with clinically relevant allergens aggravates allergen induced pathology and is contraindicated for allergen immunotherapy. Mol Immunol 2007; 44:1879-1887.
44. Meiler F, Zumkehr J, Klunker S, et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205:2887-2898.
45. von Mutius E. Allergies, infections and the hygiene hypothesis: the epide-miological evidence. Immunobiology 2007; 212:433-439.